<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265616</url>
  </required_header>
  <id_info>
    <org_study_id>RSE study, protocol#62/06</org_study_id>
    <nct_id>NCT00265616</nct_id>
  </id_info>
  <brief_title>Treatment of Refractory Status Epilepticus</brief_title>
  <official_title>A Randomized Clinical Trial for the Treatment of Refractory Status Epilepticus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether propofol or barbiturates should be
      preferred in the treatment of status epilepticus (continuous seizure activity) refractory to
      2 standard antiepileptic agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Refractory status epilepticus (SE) develops in 31%-44% of patients with SE, with a mortality
      of 16%-23%. Coma induction is advocated for its management. Propofol and barbiturates are the
      most used agents, but no comparative study has been performed. In consideration of the
      uncertainty regarding the relative effectiveness, despite several retrospective data, a
      prospective investigation is needed.

      The objective is to assess the effectiveness (SE control, adverse events) of a first course
      of propofol versus barbiturates in the treatment of refractory SE, in adults with refractory
      SE not due to cerebral anoxia.

      Comparison: Coma induction with standardized doses of propofol or barbiturates titrated
      towards burst-suppression on EEG, then assessment of the proportion of patients achieving a
      control of SE.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment
  </why_stopped>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Refractory Status Epilepticus Controlled With First Course of Study Drug</measure>
    <time_frame>after return of continuous EEG activity (typically after 36 hours - 5 days)</time_frame>
    <description>Control of status epilepticus refractory to benzodiazepines and a first antiepileptic drug after administration of the study drug; dichotomous assessment (yes/no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome at Day 21</measure>
    <time_frame>21 days</time_frame>
    <description>Return to baseline clinical conditions (i.e.: no new handicap, no death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Infectious Complications Requiring Specific Treatment</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Hypotension Requiring Specific Treatment</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Propofol Infusion Syndrome</measure>
    <time_frame>10 days</time_frame>
    <description>Propofol infusion syndrome (PRIS) is a severe metabolic alteration with elevation of lactate, CK, and triglycerides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intubation Time in Survivors</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Status Epilepticus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>propofol, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>thiopental/pentobarbital, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>liquid, mg/kg.h, titrated after EEG</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Disoprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiopental/pentobarbital</intervention_name>
    <description>liquid, mg/kg.h, titrated after EEG</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Pentotal /Thiopentone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with refractory status epilepticus not due to cerebral anoxia, needing coma
             induction for clinical management.

        Exclusion Criteria:

          -  Age &lt; 16 years old.

          -  Known pregnancy.

          -  Cerebral anoxia as SE etiology.

          -  Epilepsia partialis continua (simple partial SE).

          -  Known intolerance to the study drugs.

          -  Known mitochondrial disorder, hyperlipidemia, or significant rhabdomyolysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea O. Rossetti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BrighamHospital/CHUV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <state>BE</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <state>VD</state>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rossetti AO, Milligan TA, Vulliémoz S, Michaelides C, Bertschi M, Lee JW. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care. 2011 Feb;14(1):4-10. doi: 10.1007/s12028-010-9445-z.</citation>
    <PMID>20878265</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2005</study_first_submitted>
  <study_first_submitted_qc>December 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2005</study_first_posted>
  <results_first_submitted>October 27, 2010</results_first_submitted>
  <results_first_submitted_qc>February 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2013</results_first_posted>
  <last_update_submitted>April 2, 2013</last_update_submitted>
  <last_update_submitted_qc>April 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Andrea O. Rossetti, MD</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Refractory status epilepticus,</keyword>
  <keyword>coma-induction,</keyword>
  <keyword>treatment,</keyword>
  <keyword>propofol,</keyword>
  <keyword>barbiturates,</keyword>
  <keyword>efficacy,</keyword>
  <keyword>safety.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Thiopental</mesh_term>
    <mesh_term>Pentobarbital</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Rcruitment in participating centers took part between 2006 and 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Propofol</title>
          <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG);no maximum doses defined.</description>
        </group>
        <group group_id="P2">
          <title>Thiopental/Pentobarbital</title>
          <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG); no maximum doses defined.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Propofol</title>
          <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
        </group>
        <group group_id="B2">
          <title>Thiopental/Pentobarbital</title>
          <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcome at Day 21</title>
        <description>Return to baseline clinical conditions (i.e.: no new handicap, no death)</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
          </group>
          <group group_id="O2">
            <title>Thiopental/Pentobarbital</title>
            <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcome at Day 21</title>
          <description>Return to baseline clinical conditions (i.e.: no new handicap, no death)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Infectious Complications Requiring Specific Treatment</title>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
          </group>
          <group group_id="O2">
            <title>Thiopental/Pentobarbital</title>
            <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Infectious Complications Requiring Specific Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Hypotension Requiring Specific Treatment</title>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
          </group>
          <group group_id="O2">
            <title>Thiopental/Pentobarbital</title>
            <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Hypotension Requiring Specific Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Propofol Infusion Syndrome</title>
        <description>Propofol infusion syndrome (PRIS) is a severe metabolic alteration with elevation of lactate, CK, and triglycerides.</description>
        <time_frame>10 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
          </group>
          <group group_id="O2">
            <title>Thiopental/Pentobarbital</title>
            <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Propofol Infusion Syndrome</title>
          <description>Propofol infusion syndrome (PRIS) is a severe metabolic alteration with elevation of lactate, CK, and triglycerides.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Refractory Status Epilepticus Controlled With First Course of Study Drug</title>
        <description>Control of status epilepticus refractory to benzodiazepines and a first antiepileptic drug after administration of the study drug; dichotomous assessment (yes/no)</description>
        <time_frame>after return of continuous EEG activity (typically after 36 hours - 5 days)</time_frame>
        <population>Number of patients fulfilling primary outcome criteria</population>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
          </group>
          <group group_id="O2">
            <title>Thiopental/Pentobarbital</title>
            <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
          </group>
        </group_list>
        <measure>
          <title>Refractory Status Epilepticus Controlled With First Course of Study Drug</title>
          <description>Control of status epilepticus refractory to benzodiazepines and a first antiepileptic drug after administration of the study drug; dichotomous assessment (yes/no)</description>
          <population>Number of patients fulfilling primary outcome criteria</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intubation Time in Survivors</title>
        <time_frame>Up to 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
          </group>
          <group group_id="O2">
            <title>Thiopental/Pentobarbital</title>
            <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
          </group>
        </group_list>
        <measure>
          <title>Intubation Time in Survivors</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="28"/>
                    <measurement group_id="O2" value="13.5" lower_limit="8" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Propofol</title>
          <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
        </group>
        <group group_id="E2">
          <title>Thiopental/Pentobarbital</title>
          <description>titrated to electroencephalographic burst-suppression (intravenous load as per protocol, then following the EEG)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>propofol infusion syndrome (non fatal)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>paralytic ileus (fatal)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Andrea O. Rossetti</name_or_title>
      <organization>CHUV Lausanne</organization>
      <phone>+41 21 314 1190</phone>
      <email>andrea.rosseti@chuv.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

